A recently commercialized product—the Proclarix—incorporating THBS1, CTSD, tPSA and % of fPSA, combined with patient age, yielded a significantly better diagnostic accuracy compared to either PSA or % of fPSA alone in discriminating clinically significant from no or insignificant prostate cancer [43,44]. This evidence concerns the gene PROS1 and prostate carcinoma.